A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
"You need to understand that we're about to embark on the busiest week of the year for industrial earnings," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Boston Federal Reserve President Eric Rosengren is lining up against an apparent push to cut interest rates, telling CNBC in an interview Friday that the central bank can...The Fedread more
The MTA reported that the 1, 2, 3, 4, 5 and 6 trains are all facing delays due to a network communications issue impacting service in both directions, NBC New York reports.Transportationread more
Companies aren't waiting for the U.S.-China trade war to be resolved, says the head of the world's biggest money manager.Investingread more
US officials including Treasury Secretary Steven Mnuchin and White House economic adviser Larry Kudlow will host a meeting at the White House on Monday of semiconductor and...Technologyread more
Trump's constant berating of the Fed and its actions does not influence the central bank's decisions, Boston Fed's Eric Rosengren says.The Fedread more
The lawsuits allege J&J's talc-based baby powder contained asbestos and caused ovarian and other cancers.Health and Scienceread more
If you're willing to speculate, Cramer wants you to know about the company behind this potential breakthrough cancer drug.
"I'm talking about Pharmacyclics, " said Cramer, the maker of . " "Currently the drug is being studied as a treatment for different types of blood cancers including chronic lymphocytic leukemia, mantle cell lymphoma, and multiple myeloma."
Results are quite promising. The clinical trial data for Ibrutinib has been very strong.
In fact results are so strong, "The Food and Drug Administration already considers —that's the designation the FDA gives to drug candidates that it feels are transformational. And Ibrutinib has received this breakthrough drug designation three times over, " Cramer said.
"If approved, Pharmacyclics plans to charge $125,000 a year for Ibrutinib, which sounds exorbitant but is actually pretty standard for these . Based on that pricing, the analysts who just initiated coverage on Pharmacyclics at JP Morgan think this drug can do $6.5 billion in peak sales as a treatment for chronic lymphocytic leukemia and mantle cell lymphoma, " Cramer said.
Under the terms of an agreement, sales of the drug are split equally with Johnson & Johnson, leaving Pharmacyclics with $3.25 billion per year.
Now, the promise of the drug has not gone unnoticed on Wall Street. Already, shares have rallied 125% ytd and 1,577% over the last 3 years. "
Typically Cramer would not advocate chasing a stock with those kinds of gains. However, this time, he's making an exception.
That's because the company is looking at Ibrutinib as treatments for other blood cancers, and JP Morgan only estimated peak sales for the two applications that are furthest along.
Looking at more indications, analysts at William Blair figure that Pharmacyclics could have a $9.2 billion drug on their hands.
And Cramer sees other reasons to like this stock.
Read More from Mad Money with Jim Cramer
Cramer: 10 stocks big money is buying
Domestic stock beyond DC's reach
Massive fine bargain for investors: Cramer
"Pharmacyclics has a healthy pipeline of other drugs, including a pancreatic cancer drug in phase 2 development, a drug for lymphoma and solid tumors that's also in phase two, and a couple of preclinical programs that might eventually amount to something years and years from now," Cramer said.
All told, the Mad Money host sees every reason for the stock to rally further.
However, as in the case with all investments that are largely a bet on the success of a drug, Cramer reminds the play is a spec. "It's always possible somebody else will invent a better mousetrap," Cramer said.
Therefore, Cramer would play this one with options. "I would buy deep in the money call options to get maximum upside while still being stopped out on the downside."
Call Cramer: 1-800-743-CNBC
Questions for Cramer? firstname.lastname@example.org
Questions, comments, suggestions for the "Mad Money" website? email@example.com